FTSE MIB
34.217,65 +492,83 (+1,46%) Dow Jones
38.415,98 +176,00 (+0,46%) Nasdaq
15.675,04 +223,73 (+1,45%) Nikkei 225
37.552,16 +113,55 (+0,30%) Petrolio
82,20 +0,30 (+0,37%) Bitcoin EUR
62.694,15 +777,07 (+1,26%)
Grifols, S.A. (GRFS)
| Chiusura precedente | 6,30 |
| Aperto | 6,49 |
| Denaro | 6,58 x 800 |
| Lettera | 6,63 x 400 |
| Min-Max giorno | 6,45 - 6,66 |
| Intervallo di 52 settimane | 5,30 - 12,15 |
| Volume | |
| Media Volume | 2.148.400 |
| Capitalizzazione | 5,578B |
| Beta (5 anni mensile) | 0,68 |
| Rapporto PE (ttm) | 66,15 |
| EPS (ttm) | 0,10 |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 03 giu 2021 |
| Stima target 1A | 15,81 |
GlobeNewswireGigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade GigaGen and NCI will present investigational new drug (IND)-enabling data and clinical trial strategy for GIGA-564 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN CARLOS, Calif., Sept. 28, 2023 (GLOBE NEWSW
GlobeNewswireGrifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics
Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce the robustness of its therapeutic pipeline and strengthen its innovation culture BARCELONA, Spain, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people’s health and
- GlobeNewswire
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients with primary immunodeficienciesStudy designed to support extending U.S. Food and Drug Administration labeling of XEMBIFY® to include biweekly dosing, providing added flexibility and convenience for patientsGrifols is accelerating adoption of XEMBIFY® as part of its broader immunoglobulin business st
